Online semaglutide: low purity, wrong amounts, and endotoxin
Test purchases of online 'semaglutide' found purity around 7-14% against 99% advertised, wrong amounts, and elevated endotoxin in one sample.
Test purchases of online 'semaglutide' found purity around 7-14% against 99% advertised, wrong amounts, and elevated endotoxin in one sample.

Researchers at the University of Pecs in Hungary, with coauthor Tim K. Mackey of UC San Diego, reported in JAMA Network Open on August 2, 2024 what they found when they tried to buy semaglutide from illegal online pharmacies operating without a prescription.
They made six test purchases. Only three products arrived, and all three were vials — the advertised prefilled pens turned out to be non-delivery scams that demanded an extra $650 to $1,200 in "customs" payments before shipping. When the three vials did arrive, their packaging scored only 8 to 9 out of 22 on the International Pharmaceutical Federation's checklist, against a 22 for the genuine product.
Liquid chromatography–mass spectrometry confirmed that semaglutide was present in all three samples. But the purity was only about 7 to 14% against the 99% the sellers advertised, and every sample held more semaglutide than its label claimed. One sample also showed elevated endotoxin.
The takeaway is that purity, content, and endotoxin are three separate questions, and in this market all three failed in different ways. A product can contain the right molecule (identity passes) yet be mostly not that molecule (purity fails), hold more than the label says (content fails), and carry bacterial endotoxin (safety fails) — all at once. None of that is visible from a label or a photograph of a vial.
This is why a certificate of analysis that reports only "purity 99%" is not enough on its own. Identity, purity, net content, and endotoxin each need their own line on the report, each run against a specification.
Ashraf AR et al. JAMA Network Open. Published August 2, 2024.
Study2017A 2017 JAMA study found only about half of products sold online as SARMs actually contained a SARM, and many held a different unapproved drug instead.
Study2024How researchers map and audit an unregulated online peptide market, from search surveillance to lab testing.
Regulator2024The WHO estimates at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified.